1. Presentation Order
| Order | Presentation Time | Title | First Name | Last Name | Country | Paper Title | Theme |
| 1 | 1520 – 1530 | Prof | Chung-Feng | Huang | Taiwan | Establishment of an outreach, grouping health care system to achieve micro-elimination of HCV for uremic patients in hemodialysis centers (ERASE-C) | Hepatitis B and Hepatitis D |
| 2 | 1530 – 1540 | Prof | Man-Fung | Yuen | China | Preliminary results of a Phase 2 study of VIR-2218, an X-targeting RNAi therapeutic, in patients with chronic hepatitis B: sub-analyses of HBeAg-negative and HBeAg-positive patients | Hepatitis B and Hepatitis D |
| 3 | 1540 – 1550 | Dr | Gane | Edward | New Zealand | Safety and Efficacty of Oral TLR8 Agonist, Selgantolimod (SLGN), in Virally-Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study | Hepatitis C |
| 4 | 1550 – 1600 | Dr | Zhi-Hong | Liu | China | A randomized, double-blind, phase 3, non-inferiority, 48 weeks trial: tenofovir amibufenamide versus tenofovir disoproxil fumarate for the treatment of chronic hepatitis B virus infection. | Hepatitis C |
| 5 | 1600 – 1610 | Dr | Wen-Yu | Wu | China | Exosomes with miR-574 transfer anti-HBV activity mediated by the interferon from macrophage to HBV-infected hepatocyte | Hepatitis C |
| 6 | 1610 – 1620 | Prof | Masatoshi | Kudo | Japan | The Novel Regimen of a Single, Priming Dose of Tremelimumab (T) + Durvalumab (D) in Patients With Unresectable Hepatocellular Carcinoma (uHCC) by Viral Etiology | Hepatobiliary Neoplasia |
| 7 | 1620 – 1630 | Dr | Masafumi | Ikeda | Japan | IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in unresectable hepatocellular carcinoma (HCC) | Inflammation and Immunobiology |
| 8 | 1630 – 1640 | Dr | Mei-Yi | Song | China | MiR-24 Regulates Hepatic stellate cells Activation by Targeting ALK4 in Liver Fibrosis | Liver Fibrogenesis and Non-Parenchymal Cell Biology |
| 9 | 1640 – 1650 | Dr | Vincent | Wong | China | Safety and Efficacy of Combination Therapies Including Cilofexor/Firsocostat in Patients With Bridging Fibrosis and Cirrhosis Due to NASH: Results of the Phase 2b ATLAS Trial | NAFLD and NASH |
| 10 | 1650 – 1700 | Ms | Meng-Yang | Zhang | China | Disappeared steatosis relates to fibrosis regression in on-treatment patients with chronic hepatitis B | Hepatitis B and Hepatitis D |
2. Scientific Programme
a. All presentations will be pre-recorded and released at a scheduled time on the event programme.
b. All Oral Presenters are given 10 minutes each - 8 minutes for presentation (pre-recorded) and 2 minutes for LIVE Q & A. If the presentation exceeds the time assigned, the Q&A time will be shorted accordingly.
c. Attendees and Oresenters will be able to engage with one another using the interactive Q & A feature to pose and address questions in real time when the presentation is played. Presenters are requested to be present to participate during their assigned presentation time.
Important : Please review APASL2021 Agreement and Presentation Preparation Guidelines and Technical Guide.
3. Presentation recording
Please review Recording a Presentation for APASL 2021_Free Papers before you commence recording.
a. Tips on Presentation and Recording
b. Use APASL2021 Official Slide Template
c. Use APASL2021 Virtual Backgrounds provided, option 1 and option 2
d. Save the recorded file name as: date of presentation time of presentation your name
Example: 04.02.2021_15:30_John Smith
e. Upload file to dropbox: click here
f. Deadline for submission: 29 January 2021